For Healthcare Professionals

Single Dose Study of PF-06815345 in Healthy Subjects

clipboard-pencil

About the study

The current study is the first clinical trial proposed with PF-06815345. It is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) following administration of single oral doses of PF-06815345 to healthy adult subjects.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. Healthy males and female of non-childbearing potential;
  2. Age of 18-55, inclusive;
  3. Body Mass Index 17.5-34.9 kg/m2, inclusive;
  4. Body weight >50 kg;
  5. Not on any prescription or non-prescription drugs within 7 days or 5 half-lives prior to first dose.

EXCLUSION CRITERIA

  1. Evidence of history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergises, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 1-800-718-1021

Study’s details


Contition

Hypercholesterolemia

Age

18+

Phase

Phase 1

Participants needed

25

Est. Completion Date

Jul 2016

Treatment type

Interventional


Sponsor

Pfizer

ClinicalTrials.gov identifier

NCT02654899

Study number

C0281001

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.